Progress in treatment of mantle cell lymphoma
10.3760/cma.j.issn.1009-9921.2017.03.006
- VernacularTitle:套细胞淋巴瘤治疗进展
- Author:
Luo LU
;
Li WANG
;
Wei XU
- Keywords:
Mantle cell lymphoma;
American Society of Hematology Annual Meeting
- From:
Journal of Leukemia & Lymphoma
2017;26(3):148-151
- CountryChina
- Language:Chinese
-
Abstract:
Mantle cell lymphoma (MCL), being a kind of aggressive non-Hodgkin ' s lymphoma (NHL), accounts for 6 % - 8 % of NHL in adults which is characterized by malignant B cell infiltration of lymph node, gastrointestinal tract and bone marrow. MCL commonly responds to initial therapy but inevitably occurs relapse and drug resistance. The study on MCL in the 58th American Society of Hematology Annual Meeting has covered many aspects such as basic research, clinical treatment and new drug research. The development of novel mouse model and the exploration of signaling pathways provide a basis for the improvement of MCL pathogenesis and new drug research. VcR-CVAD, VCR and some other chemotherapy regimens designed for different patients have showed satisfactory results. New drugs such as inhibitors of CDK, PI3K and bcl-2 in initial clinical trials are also promising. IACS-010759 and other small molecules provide new directions for the treatment of MCL.
